Determination of tumor kinetics: Strategies for the delivery of radiotherapy and chemotherapy

Current Opinion in Oncology

Volumn 11, Issue 3, 1999, Pages 177-182

  Ritter, Mark A ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER; CELL KINETICS; CELL PROLIFERATION; FRACTIONATION; PRIORITY JOURNAL; REVIEW; TUMOR CELL;

CELL CYCLE; CELL DIVISION; HEAD AND NECK NEOPLASMS; HUMANS; KINETICS;

EID: 0032949589     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199905000-00007     Document Type: Review

References (71)

1. 125I implantation. Int J Radiat Oncol Biol Phys 1991, 21:537-547.
2. Suit HD, Westgate SJ: Impact of improved local control on survival. Int J Radiat Oncol Biol Phys 1986, 12:453-458.
3. Suit HD: Local control and patient survival. Int J Radiat Oncol Biol Phys 1992, 23:653-660.
4. Nordsmark M, Overgaard M, Overgaard J: Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 1996, 41:31-39.
5. West CM, Davidson SE, Hunter RD: Evaluation of surviving fraction at 2 Gy as a potential prognostic factor for the radiotherapy of carcinoma of the cervix. Int J Radiat Biol Phys 1989, 56:761-765.
6. Maciejewski B, Preuss-Bayer G, Trott KR: The influence of the number of fractions and of the overall treatment time on local control and late complication rate in squamous cell carcinoma of the larynx. Int J Radiat Oncol Biol Phys 1983, 9:321-328.
7. Parsons JT, Bova FJ, Million RR: A re-evaluation of split-course techniques for squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1980, 6:1645-1652.
8. Withers HR, Taylor JM, Maciejewski B: The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol 1988, 27:131-146.
9. Fowler JF, Tanner MA, Bataini JP, Asselain B, Bernier J, Lave C: Further analysis of the time factor in squamous cell carcinoma of the tonsillar region. Radiother Oncol 1990, 19:237-244.
10. 4 squamous cell carcinoma of the larynx. Int J Radiat Oncol Biol Phys 1991, 21:813-817.
11. Pajak TF, Laramore GE, Marcial VA, Fazekas JT, Cooper J, Rubin P, et al.: Elapsed treatment days - a critical item for radiotherapy quality control review in head and neck trials: RTOG report. Int J Radiat Oncol Biol Phys 1991, 20:13-20.
12. Keane TJ, Fyles A, O'Sullivan B, Barton M, Simm J: The effect of treatment duration on local control of squamous carcinoma of the tonsil and carcinoma of the cervix. Semin Radiat Oncol 1992, 2:26-28.
13. Overgaard M, Hjelm-Hansen M, Vendelbo JL: Comparison of conventional and split-course radiotherapy as primary treatment in carcinoma of the larynx. Acta Oncol 1988, 27:147-161.
14. Taylor JM, Withers HR, Mendenhall WM: Dose-time considerations of head and neck squamous cell carcinomas treated with irradiation. Radiother Oncol 1990, 17:95-102.
15. Wang CC: Local control of oropharyngeal carcinoma after two accelerated hyperfractionation radiation therapy schemes. Int J Radiat Oncol Biol Phys 1988, 14:1143-1146.
16. Cox JD, Pajak TF, Marcial VA, Coia L, Mohiuddin M, Fu KK, et al.: Interruptions adversely affect local control and survival with hyperfractionated radiation therapy of carcinomas of the upper respiratory and digestive tracts. New evidence for accelerated proliferation from Radiation Therapy Oncology Group Protocol 8313. Cancer 1992, 69:2744-2748.
17. Le QT, Fu KK, Kroll S, Ryu JK, Quivey JM, Meyler TS, et al.: Influence of fraction size, total dose, and overall time on local control of T1-T2 glottic carcinoma. Int J Radiat Oncol Biol Phys 1997, 39:115-126. Total dose, fraction size, and overall time were significant factors for local control of T2 but not T1 glottic carcinomas.
18. Robertson C, Robertson AG, Hendry JH, Roberts SA, Slevin NJ, et al.: Similar decreases in local tumor control are calculated for treatment protraction and for interruptions in the radiotherapy of carcinoma of the larynx in four centers. Int J Radiat Oncol Biol Phys 1998, 40:319-329. Any gaps in the treatment schedule have the same deleterious effect on the disease-free period as an increase in the prescribed treatment time. For a schedule in which dose and fraction number are specified, any gap in treatment is potentially damaging.
19. Saarilahti K, Kajanti M, Lehtonen H, Hamalainen T, Joensuu H: Repopulation during radical radiotherapy for T1 glottic cancer. Radiother Oncol 1998, 47:155-159. Repopulation should be taken into account even when treating small T1 laryngeal cancer, and protraction of the overall treatment time should be avoided.
20. Hendry JH, Bentzen SM, Dale RG, Fowler JF, Wheldon TE, Jones B, et al.: A modelled comparison of the effects of using different ways to compensate for missed treatment days in radiotherapy. Clin Oncol (R Coll Radiol) 1996, 8:297-307.
21. Roberts SA, Hendry JH, Slevin NJ: Modelling the optimal radiotherapy regime for the control of T2 laryngeal carcinoma using parameters derived from several datasets. Int J Radiat Oncol Biol Phys 1997, 39:1173-1182.
22. Tsuchida E, Urano M: The effect of UCN-01 (7-hydroxystaurosporine), a potent inhibitor of protein kinase C, on fractionated radiotherapy or daily chemotherapy of a murine fibrosarcoma. Int J Radiat Oncol Biol Phys 1997, 39:1153-1161.
23. Ritter MA: Proliferation-targeted therapy. In Volume and Kinetics in Tumor Control and Normal Tissue Complications. Edited by Paliwał BR, Fowler JE, Herbert DE, Mehta MP. Madison, WI: Medical Physics Publishing, 1998:193. Continuously applied antiproliferative agents can reduce the amount of intrafraction repopulation that occurs in a multicellular spheroid model system. A phase I trial using low dose hydroxyurea during radiotherapy is being carried out in carcinoma of the cervix.
24. Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, et al.: Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med 1995, 332:1317-1322.
25. Urtasun RC, Kinsella TJ, Farnan N, DelRowe JD, Lester SG, Fulton DS: Survival improvement in anaplastic astrocytoma, combining external radiation with halogenated pyrimidines: final report of RTOG 86-12, Phase I-II study [see comments]. Int J Radiat Oncol Biol Phys 1996, 36:1163-1167.
26. Horiot JC, Bontemps P, van den Bogaert W, Le Fur R, van den Weijngaert D, Bolla M, et al.: Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial [abstract]. Radiother Oncol 1997, 44:111-121. This trial shows that accelerated radiotherapy improves locoregional control in head and neck squamous cell carcinomas, but the regimen demonstrated high late toxicities. Alternative regimens are suggested that still allow accelerated delivery of radiation.
27. Overgaard J, Sand-Hansen H, Sapru W, Overgaard M, Grau C, Iorgensen K, et al.: Conventional radiotherapy as the primary treatment of squamous cell carcinoma (SCC) of the head and neck. A randomised multicenter study of 5 versus 6 fractions per week. Preliminary report from the Dahanca 6 and 7 trial [abstract]. Radiother Oncol 1996, 40(Suppl 1):31.
28. Dische S, Saunders M, Barrett A, Harvey A, Gibson D, Parmar M: Arandomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother Oncol 1997, 44:123-136. Similar local tumor control was achieved by continuous hyperfractionated accelerated radiotherapy (CHART) as compared with conventional radiotherapy despite the reduction in total dose from 66 Gy to 54 Gy supporting the importance of repopulation as a cause of radiation failure. Reduced late morbidity was also noted.
29. Ang KK: Impact of overall time factor of radiation or combined therapy on the treatment outcome of advanced head and neck cancer. In: Volume and Kinetics in Tumor Control and Normal Tissue Complications. Edited by Paliwal BR, et al. Madison, WI: Medical Physics Publishing; 1998:289-306. Accelerated radiotherapy in a postoperative head and neck setting was found to produce superior local control compared with conventionally fractionated radiotherapy.
30. Ang KK: Accelerated fractionation: what is the price for speeding? [editorial; comment] [see comments]. Radiother Oncol 1997, 44:97-99.
31. Ang KK: Altered fractionation in the management of head and neck cancer. Int J Radiat Biol 1998, 73:395-399.
32. Adelstein DJ, Saxton JP, Lavertu P, Tuason L, Wood BG, Wanamaker JR, et al.: A phase III randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable state III and IV squamous cell head and neck cancer: preliminary results. Head Neck 1997, 19:567-575.
33. Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, et al.: Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 1998, 16:1310-1317.
34. Haffty BG, Son YH, Sasaki CT, Papac R, Fischer D, Rockwell S, et al.: Mitomycin C as an adjunct to postoperative radiation therapy in squamous cell carcinoma of the head and neck: results from two randomized clinical trials [see comments]. Int J Radiat Oncol Biol Phys 1993, 27:241-250.
35. Jaulerry C, Rodriguez J, Brunin F, Jouve M, Mosseri V, Point D, et al.: Induction chemotherapy in advanced head and neck tumors: results of two randomized trials [see comments]. Int J Radiat Oncol Biol Phys 1992, 23:483-489.
36. Paccagnella A, Orlando A, Marchiori C, Zorat PL, Cavaniglia G, Sileni VC, et al.: Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo [see comments]. J Natl Cancer Inst 1994, 86:265-272.
37. Dalley D, Beller E, Aroney R, Dewar J, Page J, Philip R, Simes J: The value of chemotherapy (CT) prior to definitive local therapy (DLT) in patients with locally advanced squamous cell carcinoma (SCC) of the head and neck (HN) [abstract]. Proc Ann Meet Am Assoc Cancer Res 1995, 14:A856.
38. Fowler JF: Rapid repopulation in radiotherapy: a debate on mechanism. The phantom of tumor treatment-continually rapid proliferation unmasked. Radiother Oncol 1991, 22:156-158.
39. Bourhis J, Wilson G, Wibault P, Janot F, Bosq J, Armand JP, et al.: Rapid tumor cell proliferation after induction chemotherapy in oropharyngeal cancer. Laryngoscope 1994, 104:468-472.
40. Tannock IF: Combined modality treatment with radiotherapy and chemotherapy. Radiother Oncol 1989, 16:83-101.
41. Parsons JT, Mendenhall WM, Cassisi NJ, Isaacs JJ, Million RR: Hyperfractionation for head and neck cancer. Int J Radiat Oncol Biol Phys 1988, 14:649-658.
42. Cox JD, Pajak TF, Marcial VA, Hanks GE, Mohiuddin M, Fu KK, et al.: Dose-response for local control with hyperfractionated radiation therapy in advanced carcinomas of the upper aerodigestive tracts: preliminary report of radiation therapy oncology group protocol 83-13. Int J Radiat Oncol Biol Phys 1990, 18:515-521.
43. Horiot JC, Le FR, N'Guyen T, Chenal C, Schraub S, Alfonsi S, et al.: Hyperfractionated compared with conventional radiotherapy in oropharyngeal carcinoma: an EORTC randomized trial. Eur J Cancer 1990, 26:779-780.
44. Begg AC, McNally NJ, Shrieve DC, Karcher H: A method to measure the duration of DNA synthesis and the potential doubling time from a single sample. Cytometry 1985, 6:620-626.
45. pot in cancer of the uterine cervix: correlation between two laboratories and preliminary clinical results. Int J Radiat Oncol Biol Phys 1995, 32:1319-1329.
46. Bourhis J, Dendale R, Hill C, Bosq J, Janot F, Attal P, et al.: Potential doubling time and clinical outcome in head and neck squamous cell carcinoma treated with 70 GY in 7 weeks. Int J Radiat Oncol Biol Phys 1996, 35:471-476.
47. Corvo R, Giaretti W, Sanguineti G, Geido E, Orecchia R, Guenzi M, et al.: In vivo cell kinetics in head and neck squamous cell carcinomas predicts local control and helps guide radiotherapy regimen. J Clin Oncol 1995, 13:1843-1850.
48. pot the labeling index in these patients treated with radiation.
49. Zackrisson B, Gustafsson H, Stenling R, Flygare P, Wilson GD: Predictive value of potential doubling time in head and neck cancer patients treated by conventional radiotherapy. Int J Radiat Oncol Biol Phys 1997, 38:677-683. Potential doubling time provides clinically important information that can predict that a patient will have a low probability of achieving long-term local control with conventional fractionation.
50. Hoyer M, Jorgensen K, Bundgaard T, Johansen LV, Bentzen SM, Overgaard M, et al.: Lack of predictive value of potential doubling time and iododeoxyuridine labelling index in radiotherapy of squamous cell carcinoma of the head and neck. Radiother Oncol 1998, 46:147-155.
51. Bolger BS, Symonds RP, Stanton PD, MacLean AB, Burnett R, Kelly P, Cooke TG: Prediction of radiotherapy response of cervical carcinoma through measurement of proliferation rate. Br J Cancer 1996, 74:1223-1226.
52. White RA, Terry NH, Meistrich ML, Calkins DP: Improved method for computing potential doubling time from flow cytometric data. Cytometry 1990, 11:314-317.
53. Bennett MH, Wilson GD, Dische S, Saunders MI, Martindale CA, Robinson BM, et al.: Tumour proliferation assessed by combined histological and flow cytometric analysis: implications for therapy in squamous cell carcinoma in the head and neck. Br J Cancer 1992, 65:870-878.
54. Ritter MA, Fowler JF, Kim Y, Lindstrom MJ, Kinsella TJ: Single biopsy, tumor kinetic analyses: A comparison of methods and an extension to shorter sampling intervals. Int J Radiat Oncol Biol Phys 1992, 23:811-820.
55. Ritter MA, Albrechtson JL, Kim YJ, Kinsella TJ: Tumor cell kinetics in mixed populations. Cytometry 1994, 16:118-128.
56. Boker DK, Stark HJ: The proliferation rate of intracranial tumors as defined by the monoclonal antibody KI 67. Application of the method to paraffin embedded specimens. Neurosurg Rev 1988, 11:267-272.
57. Garcia RL, Coltrera MD, Gown AM: Analysis of proliferate grade using anti-PCNA/cyclin monoclonal antibodies in fixed, embedded tissues. Comparison with flow cytometric analysis. Am J Pathol 1989, 134:733-739.
58. Mann GJ, Musgrove EA, Fox RM, Thelander L: Ribonucleotide reductase M1 subunit in cellular proliferation, quiescence, and differentiation. Cancer Res 1988, 48:5151-5156.
59. Fu KK, Hammond E, Pajak TF, Clery M, Doggett RL, Byhardt RW, et al.: Flow cytometric quantification of the proliferation-associated nuclear antigen p105 and DNA content in advanced head & neck cancers: results of RTOG 91-08. Int J Radiat Oncol Biol Phys 1994, 29:661-671.
60. Schrape S, Jones DB, Wright DH: A comparison of three methods for the determination of the growth fraction in non-Hodgkin's lymphoma. Br J Cancer 1987, 55:283-286.
61. Silvestrini R, Costa A, Veneroni S, Del BG, Persici P: Comparative analysis of different approaches to investigate cell kinetics. Cell Tissue Kinet 1988, 21:123-131.
62. Veneroni S, Costa A, Motta R, Giardini R, Rilke F, Silvestrini R: Comparative analysis of [3H]-thymidine labelling index and monoclonal antibody Ki-67 in non-Hodgkin's lymphomas. Hematol Oncol 1988, 6:21-28.
63. Kamel OW, Franklin WA, Ringus JC, Meyer JS: Thymidine labeling index and Ki-67 growth fraction in lesions of the breast. Am J Pathol 1989, 134:107-113.
64. Dong H, Bertler C, Schneider E, Ritter MA: Assessment of cell proliferation by AgNOR scores and Ki-67 labeling indices and a comparison with potential doubling times. Cytometry 1997, 28:280-288. This study found that Ki-67 and AgNOR scores correlated well with the potential doubling time over a wide range of proliferation rates in two in vitro systems in which proliferation rate varied.
65. Wilson GD, Saunders MI, Dische S, Daley FM, Robinson BM, Martindale CA, et al.: Direct comparison of bromodeozyuridine and Ki-67 labelling indices in human tumours. Cell Prolif 1996, 29:141-152.
66. Oka K, Arai T: MIB1 growth fraction is not related to prognosis in cervical squamous cell carcinoma treated with radiotherapy. Int J Gynecol Pathol 1996, 15:23-27.
67. Ploton D, Menager M, Jeannesson P, Himber G, Pigeon F, Adnet JJ: Improvement in the staining and in the visualization of the argyrophilic proteins of the nucleolar organizer region at the optical level. Histochem J 1986, 18:5-14.
68. Dervan PA, Gilmartin LG, Loftus BM, Carney DN: Breast carcinoma kinetics. Argyrophilic nucleolar organizer region counts correlate with Ki67 scores. Am J Clin Pathol 1989, 92:401-407.
69. Crocker J, Macartney JC, Smith PJ: Correlation between DNA flow cytometric and nucleolar organizer region data in non-Hodgkin's lymphomas. J Pathol 1988, 154:151-156.
70. Vail DM, Kisseberth WC, Obradovich JE, Moore FM, London CA, MacEwen EG, Ritter MA: Assessment of potential doubling time (Tpot), argyrophilic nucleolar organizer regions (AgNOR), and proliferating cell nuclear antigen (PCNA) as predictors of therapy response in canine non-Hodgkin's lymphoma. Exper Hematol 1996, 24:807-815.
71. Wilson GD: Flow cytometric detection of proliferation-associated antigens, PCNA and Ki-67. Methods Mol Biol 1998, 80:355-363.